Stay updated with breaking news from Bill Enright. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
On Friday, Barinthus Biotherapeutics plc (NASDAQ:BRNS), formerly Vaccitech plc, released topline final data from the APOLLO trial (...
Explore the latest findings from Barinthus Biotherapeutics on VTP-200's performance in the APOLLO trial for low-grade cervical lesions linked to persistent hrHPV infection. Positive trends were noted, though not statistically significant. No major safety concerns were observed.
Primary safety endpoint met; VTP-200 was generally well-tolerated, with no treatment-related grade 3 or higher adverse events or serious AEs . Positive trends in clearance rate for both high-risk HPV...
18.04.2024 - Primary safety endpoint met; VTP-200 was generally well-tolerated, with no treatment-related grade 3 or higher adverse events (AEs) or serious AEs (SAEs). Positive trends in clearance rate for both high-risk (hr)HPV (60%, Group 2) and cervical ... Seite 1
CEPI to invest funding of up to $34.8 million to Barinthus Bio in addition to funds previously committed to the University of Oxford to develop and stockpile a ready reserve of emergency MERS vaccine...